SCHEMBL2383306

SCHEMBL2383306

Oc1ccc2ccccc2c1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.52
MAPT P10636 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ALOX5 P09917 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
LMNA P02545 2/20 0.46
HSD17B10 Q99714 2/20 0.46
PTGS1 P23219 1/20 0.46
SLC6A2 P23975 1/20 0.46
PTGS2 P35354 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HIF1A Q16665 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CYP2C9 P11712 1/20 0.46
PTPN22 Q9Y2R2 1/20 0.46
KDM4E B2RXH2 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6627314 0.81 NPC1 (0.48) MAOBMAPTL3MBTL1NPC1RAB9A
SCHEMBL8859833 0.81 NPC1 (0.62) MAPTL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL29097577 0.79 RAB9A (0.49) MAOBMAPTL3MBTL1NPC1RAB9A
SCHEMBL1681386 0.79 WDR5 (0.53) MAPTL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL7595465 0.79 ALOX5 (0.54) MAPTALOX5CYP1A2CYP2C19HSD17B10
SCHEMBL9409815 0.78 ALOX5 (0.53) MAPTL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL7088137 0.78 NPC1 (0.55) MAOBMAPTL3MBTL1NPC1RAB9A
SCHEMBL4885527 0.77 IDO1 (0.54) MAPTL3MBTL1ALOX5CYP1A2CYP2C19
SCHEMBL12303122 0.77 MAPT (0.54) MAPTL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL5113606 0.76 TDP1 (0.53) MAPTL3MBTL1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 MAOB 1381/4885MAPT 4511/4885L3MBTL1 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.